Navigation Links
First gene therapy for heart failure offered at NewYork-Presbyterian/Columbia
Date:6/18/2008

NEW YORK (June 18, 2008) -- Could injecting a gene into a patient with severe heart failure reverse their disabling and life-threatening condition? Physician-scientists are setting out to answer that question in a first-ever clinical trial of gene therapy to treat severe heart failure.

NewYork-Presbyterian Hospital/Columbia University Medical Center is the only center in the New York City area where the therapy is currently available.

Patients enrolled in the multicenter CUPID trial (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease) will undergo a minimally invasive cardiac catheterization procedure that will introduce a specially engineered gene that stimulates production of an enzyme necessary for the heart to pump more efficiently.

"This new therapy seeks to replenish the levels of this enzyme by introducing the gene for SERCA2a, which is depressed in these patients. If proven effective, this approach could be an alternative to heart transplant for patients without any other options," says Dr. Donna Mancini, the study's principal investigator at NewYork-Presbyterian Hospital/Columbia University Medical Center, where she is medical director of cardiac transplantation. She also is professor of medicine at Columbia University College of Physicians and Surgeons.

Gene therapy is a technique for correcting defective genes responsible for disease development by inserting genes into a patient's cells and tissues. In most gene therapy studies, a "normal" gene is inserted into the genome to replace an "abnormal" disease-causing gene. A carrier molecule called a vector must be used to deliver the therapeutic gene to the patient's target cells. Currently, the most common vector is a non-pathogenic virus most people have been exposed to in adolescence that has been genetically altered to carry normal human DNA.

More than five million people in the U.S. have heart failure. Patients with severe form of the disease have trouble breathing because the heart cannot pump fluid out of their lungs. Seventy percent die of the disease within 10 years, and the five-year survival rate is less than 50 percent. Heart failure is the only cardiovascular disease whose incidence has been increasing rather than decreasing.


'/>"/>

Contact: Belinda Mager
bem9040@nyp.org
212-305-5587
New York- Presbyterian Hospital/Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. NBA All-Star and Olympic Athlete LeBron James and Dr. Ian Smith Celebrate the Launch of The 50 Million Pound Challenges First Citywide Team Challenge, Kicking off in Cleveland, Ohio
2. Decatur Memorial Hospital Becomes First in Illinois to Treat Cancer Patients With RapidArc(TM) Radiotherapy Technology
3. Vynamic Funds PAs First WARM2Kids Learning Center at Philadelphias R.W. Brown Community Center
4. AMA Provides First Ever Guidance on Medical Tourism
5. Haemacure Raises $7.8 Million and is Fully Funded Beyond First-Patient-In-Clinic
6. Presbyterian College Announces First Dean of New Pharmacy School
7. PAs First West-Nile-Positive Mosquito of 2008 Season Discovered in Luzerne County
8. UT Southwestern surgeons complete first single-incision lap-band surgery in Texas
9. UltraShape(R) Commences Pivotal Study for First Non-Invasive Fat Reduction and Body Contouring Device Using Non-Thermal Selective Focused Ultrasound
10. Neutrogena(R) Dermatologics Introduces skin iD(TM), the First Personalized Acne Solution
11. Florida Tech student earns first place in national science competition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... ... , ... Coast Dental has a new way to help parents keep their ... dentist Yvonne Dorrian, DMD, is hosting a free seminar on Friday, February 19 from ... at 1207 North Peachtree Parkway in Peachtree City. Dr. Dorrian will have healthy snacks, ...
(Date:2/8/2016)... Dallas, Texas (PRWEB) , ... February 08, 2016 , ... The Valentine’s Season is famous ... family members and significant others that they are loved. This year, for more than ... much they cost - just won't be enough to remind them of the lives they’ve ...
(Date:2/8/2016)... ... 2016 , ... Brenton Engineering , powered by Pro ... wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new solution ... or fully-automatic case packing with a small footprint, rugged, highly flexible, and cost-effective ...
(Date:2/8/2016)... ... 2016 , ... Tingley Rubber Corporation , a leading ... range of unique and advantaged protective solutions to a growing and dynamic ... customer service and marketing support. A new distribution center in Brampton, Ontario will ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell ... selected the latest beneficiary of their ongoing community enrichment program. The current campaign ... area schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
(Date:2/8/2016)... , Feb. 8, 2016  Unilife Corporation ("Unilife" or "Company") ... of injectable drug delivery systems, today announced that it will ... ended December 31, 2015 after market close on February 9, ... conference call to discuss these financial results.    ... --> About Unilife Corporation ...
(Date:2/8/2016)... Calif. , Feb. 8, 2016  Sangamo ... in therapeutic genome editing, announced that the U.S. ... Company,s Investigational New Drug (IND) application for SB-318, ... life-long therapy for Mucopolysaccharidosis Type I (MPS I). ... enables Sangamo to initiate a Phase 1/2 clinical ...
Breaking Medicine Technology: